The PROTAC functionalized compound is far more effective than small molecule inhibitors to induce AKR1C3 degradation and does so from 4 h post exposure and this translates to greater effects on cell viability of a variety of AKR1C3 differentially expressing prostate cancer cell lines. This evidence concerns the gene AKR1C3 and prostate carcinoma.